Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001019056-25-000184
Filing Date
2025-06-25
Accepted
2025-06-25 18:36:35
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9332
2 EXHIBIT 99.1 ex99_1.htm EX-99.1 7450
  Complete submission text file 0001019056-25-000184.txt   18607
Mailing Address 590 MADISON AVENUE 31ST FLOOR NEW YORK NY 10022
Business Address 590 MADISON AVENUE 31ST FLOOR NEW YORK NY 10022 212-486-3211
MAK Capital Fund LP (Filed by) CIK: 0001426156 (see all company filings)

EIN.: 980416772 | State of Incorp.: FL | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address THE MEDIAWORKS 191 WOOD LANE LONDON X0 W12 7FP
Business Address THE MEDIAWORKS 191 WOOD LANE LONDON X0 W12 7FP 44 20 3829 6230
Autolus Therapeutics plc (Subject) CIK: 0001730463 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-90550 | Film No.: 251074719
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)